BioSpace News Archive

Today, Clinical Reference Laboratory (CRL), one of the largest privately held clinical testing laboratories in the U.S., announced that it received FDA Emergency Use Authorization (EUA) and is scaling up capacity for CRL Rapid Response™, a saliva-based COVID-19 RT-PCR test that can be self-collected at home, work or any other setting.

Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announces that the Company’ s registered share capital and number of outstanding shares and votes have increased during the month of July.

Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, will host a conference call at 8:00 AM EDT on August 5, 2020, to discuss its second quarter 2020 results and progress in its clinical programs.

Synlogic, Inc., a clinical stage company bringing the transformative potential of synthetic biology to medicine, announced that Aoife Brennan, M.B. Ch.B., Synlogic’s president and chief executive officer, and other members of the executive team will present at the following virtual banking conferences:.

Sentry Data Systems, Inc., the nation’s leader in pharmacy procurement, compliance and utilization management, announced today the release of its Referral Verification System™ (RVS™), to help 340B safety net providers improve the continuity of patient care by automating patient referral relationships.

Researchers led by a team at Rosalind Franklin University of Medicine and Science have devised a new therapeutic approach to treating a rare but deadly neurodegenerative genetic disease in children.

Bellicum Pharmaceuticals, Inc., a leader in developing novel, controllable cellular immunotherapies for cancers, announced equity inducement grants to two new employees consisting of an aggregate of 3,520 stock options.

89 percent of patients who received placebo during the OPTIC Phase 3 clinical trial and then received TEPEZZA in the OPTIC-X extension trial achieved clinically significant proptosis reduction with an average of 12 months of disease, compared with six months in OPTIC

Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, an

Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will host a conference call and webcast on Friday, August 7, 2020 at 8:00 a.m. ET to report financial results for the second quarter ended June 30, 2020 and provide business updates. To access th